SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?


To: RCMac who wrote (750)6/24/1999 3:19:00 AM
From: scaram(o)ucheRead Replies (2) | Respond to of 4974
 
Waiting for three pieces of news (SIBI, CLTR, LGND) during this last week of June, the first is here. I am not surprised by the adverse reactions to Targretin, but the frequency and severity is difficult to spin.

What does this mean?......

"infrequently required concomitant growth factor therapy, and
resolved after dose reduction or discontinuation on average within 30 days in at least 93% of the patients with CTCL."

Does it mean the leukopenia and neutropenia didn't resolve in 7% of the patients?

A 17% withdrawal rate due to treatment-related stuff in psoriasis.